Omeprazole for Gastroesophageal Reflux Disease in the First 2 Years of Life: A Dose‐finding Study With Dual‐channel pH Monitoring

Bishop, Jonathan; Furman, M; Thomson, Mike

doi:10.1097/mpg.0b013e318049cbcc

Cited by 26 publications

(31 citation statements)

References 34 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After reviewing the titles and abstracts and the fulllength articles, 12 articles were selected for closer assessment and then included in our analysis. 17,18,22,[25][26][27][41][42][43][44][45][46] They are summarized in Table 1.…”

Section: Resultsmentioning

confidence: 99%

“…Children's age showed a wide range of variability ranging from 1.25 months to 18 years. The treatment duration varied widely, ranging from 2 to 24 weeks, but after 2 weeks only intra-esophageal and/or gastric pH was evaluated in 2 studies 17,41 and in 1 study also endoscopy was performed as early as within 2 weeks. 22 The median dose of omeprazole was 1 mg/kg once daily (range 0.26-3.5 mg/kg).…”

Section: Resultsmentioning

confidence: 99%

“…22 The median dose of omeprazole was 1 mg/kg once daily (range 0.26-3.5 mg/kg). In all studies omeprazole was administered as a capsule or as the capsule content dispersed in a weakly acid vehicle, except for 2 studies 17,18 where granules were dispersed in non-acid vehicles.…”

Section: Resultsmentioning

confidence: 99%

“…Most common reported adverse effects have been nausea, vomiting, diarrhea, epigastric pain, skin rash, and irritability 17,[20][21][22] but generally no severe enough for patient to discontinue the drug. Only one case of anaphylactic reaction due to omeprazole has been reported, in a 14-year-old boy.…”

Section: Omeprazole Safety and Tolerabilitymentioning

confidence: 99%

“…However, if the child accidentally chews the granules, their bitter taste may result in non-compliance with refusal of subsequent doses. 16 In two studies 17,18 omeprazole granules have been dissolved in an alkaline vehicle (8.4% bicarbonate at a concentration of 2 mg/mL) or in milk. The pharmacodynamic resulting from these alternative methods of omeprazole administration has been reported to be the same as for the intact capsule.…”

Section: Omeprazole Formulationsmentioning

confidence: 99%

See 4 more Smart Citations

Delayed-release oral suspension of omeprazole for the treatment of erosive esophagitis and gastroesophageal reflux disease in pediatric patients: a review

Monzani¹,

Oderda²

2010

CEG

View full text Add to dashboard Cite

Abstract:Omeprazole is a proton-pump inhibitor indicated for gastroesophageal reflux disease and erosive esophagitis treatment in children. The aim of this review was to evaluate the efficacy of delayed-release oral suspension of omeprazole in childhood esophagitis, in terms of symptom relief, reduction in reflux index and/or intragastric acidity, and endoscopic and/or histological healing. We systematically searched PubMed, Cochrane and EMBASE (1990 to 2009) and identified 59 potentially relevant articles, but only 12 articles were suitable to be included in our analysis. All the studies evaluated symptom relief and reported a median relief rate of 80.4% (range 35%-100%). Five studies reported a significant reduction of the esophageal reflux index within normal limits (7%) in all children, and 4 studies a significant reduction of intra-gastric acidity. The endoscopic healing rate, reported by 9 studies, was 84% after 8-week treatment and 95% after 12-week treatment, the latter being significantly higher than the histological healing rate (49%). In conclusion, omeprazole given at a dose ranging from 0.3 to 3.5 mg/kg once daily (median 1 mg/kg once daily) for at least 12 weeks is highly effective in childhood esophagitis.

show abstract